2020
LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
Llovet J, El-Khoueiry A, Vogel A, Madoff D, Finn R, Ogasawara S, Ren Z, Mody K, Li J, Siegel A, Dubrovsky L, Kudo M. LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment. Annals Of Oncology 2020, 31: s702-s703. DOI: 10.1016/j.annonc.2020.08.1132.Peer-Reviewed Original ResearchP-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
Ogasawara S, Llovet J, El-Khoueiry A, Vogel A, Madoff D, Finn R, Ren Z, Modi K, Li J, Siegel A, Dubrovsky L, Kudo M. P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment. Annals Of Oncology 2020, 31: s124-s125. DOI: 10.1016/j.annonc.2020.04.189.Peer-Reviewed Original ResearchEmbolotherapy for Hepatic Oncology: Current Perspectives and Future Directions
Bajwa R, Madoff DC, Kishore SA. Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. Digestive Disease Interventions 2020, 04: 134-147. PMID: 32832829, PMCID: PMC7437993, DOI: 10.1055/s-0040-1712146.Peer-Reviewed Original ResearchSecondary liver tumorsLiver tumorsTransarterial liver-directed therapiesLocoregional treatment strategiesLiver-directed therapiesSecondary liver cancerSelective internal radiotherapyHepatic oncologySystemic therapyBland embolizationTreatment strategiesLiver cancerInternal radiotherapyMajor causeEmbolotherapyTherapyTumorsCurrent perspectivesSupportive evidenceModalitiesChemoembolizationEmbolizationRadiotherapyCancerMortality
2019
Balloon-Assisted Blood Pressure Reduction in the Downstream Vascular Compartment to Avoid Nontarget Embolization during Transarterial Chemoembolization from the Inferior Phrenic Artery
Stein SI, Madoff DC. Balloon-Assisted Blood Pressure Reduction in the Downstream Vascular Compartment to Avoid Nontarget Embolization during Transarterial Chemoembolization from the Inferior Phrenic Artery. Journal Of Vascular And Interventional Radiology 2019, 30: 1642-1644. PMID: 31101418, DOI: 10.1016/j.jvir.2018.12.010.Peer-Reviewed Original Research
2017
Balloon-Assisted Transarterial Chemoembolization: A Nascent Strategy for the Treatment of Hepatocellular Carcinoma
Kishore S, Cheng W, Smirniotopoulos J, Madoff D. Balloon-Assisted Transarterial Chemoembolization: A Nascent Strategy for the Treatment of Hepatocellular Carcinoma. Digestive Disease Interventions 2017, 01: 115-120. DOI: 10.1055/s-0037-1603961.Peer-Reviewed Original ResearchTransarterial chemoembolizationHepatocellular carcinomaLiver-confined hepatocellular carcinomaTreatment of HCCMajority of patientsBalloon catheter systemCancer-related mortalityLow-profile cathetersConventional transarterial chemoembolizationConventional TACECurative optionTransarterial therapiesLeading causeTherapeutic strategiesMicrocatheter technologyIntratumoral administrationChemotherapeutic agentsPatientsChemoembolizationCarcinomaTreatmentNascent strategyCatheterMajorityTherapy
2010
Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma
Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY. Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma. Cancer Investigation 2010, 29: 49-55. PMID: 21166498, DOI: 10.3109/07357907.2010.535052.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationOverall survivalCutaneous melanoma metastaticExtrahepatic metastatic sitesHepatic arterial chemoembolizationMedian overall survivalLactate dehydrogenase levelsType of treatmentMelanoma metastaticRadiologic responseDisease stabilizationLiver metastasesMost patientsPatient ageArterial chemoembolizationPrognostic factorsLiver diseaseMetastatic sitesCutaneous melanomaMedical recordsDehydrogenase levelsPatientsSignificant predictorsChemoembolizationSurvival